Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

skin rash, and worsening of colitis. For full prescribing information, see package insert located here. REVLIMID® is a thalidomide analogue indicated for the treatment of adult patients with ...